focus -WSS

focus

author：knowledge 2025-09-06 04:37:13 - browse：5

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

WSS

Would Medicare drug price negotiations stall in a shutdown?

WHO recommends dropping component of many flu vaccines

FDA seeks to regulate lab

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Sudafed saga points to U.S. issues with evaluating older drugs

Bernie Sanders gets little from pharma CEOs on drug prices

Wikipedia

focus

knowledge

How one medical school became remarkably diverse

Eli Lilly reports tirzepatide MASH success during Q4 earnings

In Memoriam: Notable people who died in 2023

Data show record exodus of life scientists from academia

After affirmative action ruling, medical educators look to 'holistic review'

Paxlovid should be available without a positive Covid test

Affirmative action in medical school literally saved lives

Medicare drug price negotiation program allowed for now

Dobbs anniversary: the lost opportunity of abortion as health care

Why Eli Lilly’s earnings didn’t quite live up to the hype

knowledge

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Data show record exodus of life scientists from academia

Inequities make cancer less preventable for women: report

Juul documents reveal insider tactics on political lobbying

FDA advisers vote against ALS treatment from BrainStorm

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Wikipedia

focus

entertainment

focus